Tandospirone Enhances Cisplatin Efficacy and Reduces Distress in NSCLC Patients
Overview
Emotional distress (ED) is significantly elevated in postoperative NSCLC patients, especially those receiving chemotherapy. Tandospirone not only alleviates ED symptoms but also enhances cisplatin chemotherapy efficacy by reducing tumor cell cholesterol levels.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, with surgical resection as the primary treatment for early stages. Postoperative patients frequently experience emotional distress, including anxiety and depression, which can negatively impact quality of life and treatment outcomes. Chemotherapy as adjuvant therapy further increases the risk of ED. While anti-ED drugs are commonly used, their safety and effects on tumor progression in lung cancer patients remain unclear. This study investigates the prevalence of ED, its association with adjuvant therapies, and evaluates the dual role of tandospirone in managing ED and enhancing chemotherapy response.
Data Highlights
Group
Number of Patients
ED Prevalence (%)
Healthy Controls
192
8.9
Postoperative NSCLC Patients
1185
32.2
No Adjuvant Treatment
602
Not specified
Chemotherapy Only
80
Higher ED incidence
Chemotherapy + Other Treatments
246
Higher ED incidence
Other Treatments Without Chemotherapy
253
Lower ED incidence
Key Findings
Postoperative NSCLC patients have a significantly higher prevalence of emotional distress (32.2%) compared to healthy controls (8.9%).
Chemotherapy is an independent risk factor for increased emotional distress in NSCLC patients after surgery.
Tandospirone, an anti-anxiety drug, reduces cholesterol levels in tumor cells, enhancing their susceptibility to cisplatin-induced apoptosis.
Tandospirone alleviates emotional distress symptoms without promoting tumor growth in experimental models.
A predictive model using Random Forest achieved high accuracy (AUC 0.91) in identifying patients at risk for postoperative anxiety and depression.
Clinical Implications
Systematic screening and management of emotional distress should be integrated into postoperative care for NSCLC patients, especially those undergoing chemotherapy. Tandospirone represents a promising pharmacological option that can simultaneously improve psychological well-being and enhance chemotherapy efficacy, potentially improving overall treatment outcomes.
Conclusion
Emotional distress is prevalent and exacerbated by chemotherapy in NSCLC patients post-surgery. Tandospirone offers a dual therapeutic benefit by mitigating distress and potentiating cisplatin efficacy, supporting its use as part of comprehensive lung cancer care.
References
Study Authors/Institution/2024 -- Tandospirone Enhances Cisplatin Efficacy by Reducing Cholesterol Levels and Alleviating Distress in Patients with Non-Small Cell Lung Cancer
